Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-02 am EST
0.0294 CHF   +1.38%
11/21APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
EQ
11/16Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
EQ
11/14Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

09/07/2022 | 01:02am EST

Relief Therapeutics Holding SA / Key word(s): Conference
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

07.09.2022 / 07:00 CET/CEST


Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Geneva, Switzerland, September 7, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today announced that Jack Weinstein, Chief Financial Officer and Treasurer, will present a company overview during the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 12-14, 2022.

Date: Tuesday, September 13, 2022
Time: 1:30 pm ET

Management will host one-on-one meetings during the event. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company.

A live webcast of Relief’s presentation will be available on the Company’s website at: https://www.relieftherapeutics.com/news-and-events and will be archived for a period of 90 days after the conference.


ABOUT RELIEF

Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases and connective tissue disorders. Relief’s diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria ("PKU"). Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders (“UCDs”) and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the FDA. In addition, Relief is commercializing several legacy products via licensing and distribution partners.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com. Follow Relief on LinkedIn.
 

CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
 

 

 


Additional features:

File: Press release


End of Media Release


Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1436833

 
End of News EQS News Service

1436833  07.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1436833&application_name=news&site_id=zonebourse_sftp

ę EQS 2022
All news about RELIEF THERAPEUTICS HOLDING AG
11/21APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the ..
EQ
11/16Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 wit..
EQ
11/14Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute
MT
11/14Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Defi..
EQ
11/08Relief Therapeutics, NRx Further Extend Stay of Pending Aviptadil Dispute
MT
11/08Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay ..
EQ
11/07Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation ..
CI
11/07Relief Therapeutics' New Aviptadil Formulation Found To Be Stable In Six-month Data
MT
11/07Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 ..
EQ
10/26Relief Therapeutics, NRx Extend Stay For Pending Aviptadil Dispute
MT
More news
Financials
Sales 2022 12,0 M 12,8 M 12,8 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 129 M 138 M 138 M
Capi. / Sales 2022 10,8x
Capi. / Sales 2023 5,62x
Nbr of Employees 10
Free-Float 65,6%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,03 CHF
Average target price 0,32 CHF
Spread / Average Target 1 002%
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Paolo Galfetti Chief Operating Officer & Director
Thomas Plitz Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-52.73%138
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727